African Bundibugyo Ebolavirus Vaccine Candidate To Be Advanced To Clinical Trials 

​  

​ CEPI backs Minapharm’s Bundibugyo ebolavirus vaccine candidate, based on ProBioGen’s proprietary MVA-CR19 platform Leading African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to US$16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate, strengthening efforts to develop vaccines […]